New Key Statistics Module, Z-Score and F-Score
NYSE:GKOS Key Ratios
| Market Cap $ M | 10,637.75 |
| Enterprise Value $ M | 10,454.37 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 376.51 |
| Price/Book | 15.55 |
| Price/Sales | 17.04 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 612.00 |
| EPS (TTM) $ | -3.25 |
| Beneish M-Score | -2.94 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -49.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -55.63 |
| EV-to-EBITDA | -73.89 |
| PEG | -- |
| Shares Outstanding M | 58.98 |
| Net Margin (%) | -30.69 |
| Operating Margin % | -31.31 |
| Pre-tax Margin (%) | -31.47 |
| Quick Ratio | 4.46 |
| Current Ratio | 5.04 |
| ROA % (ttm) | -20.03 |
| ROE % (ttm) | -26.53 |
| ROIC % (ttm) | -31.77 |
| Dividend Yield % | -- |
| Altman Z-Score | 25.75 |
GKOS Number of Guru Trades
GKOS Volume of Guru Trades
Gurus Latest Trades with NYSE:GKOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NYSE:GKOS is held by these investors
Total 2
Glaukos Corp Insider Transactions
No Available Data
Guru Commentaries on NYSE:GKOS
2025 Q1
What the manager wrote
Glaukos is a medical device company focused primarily on treating ophthalmological conditions such as glaucoma and corneal health. With several commercialized products and an innovative track record, the company is in the process of launching a potential blockbuster product, iDose, which is a drug-device combination with a variety of administration/efficacy advantages in treating glaucoma. This positions Glaukos for significant growth as it addresses a critical need in the healthcare market.
News about NYSE:GKOS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers